MCID: BLD034
MIFTS: 55

Bile Duct Carcinoma malady

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Bile Duct Carcinoma

About this section

Aliases & Descriptions for Bile Duct Carcinoma:

Name: Bile Duct Carcinoma 11 13 68
Bile Duct Cancer 48 50 38
Bile Duct Neoplasms 39 68
 
Malignant Tumor of Extrahepatic Bile Duct 68
Carcinoma of Extrahepatic Bile Duct 68
Extrahepatic Bile Duct Cancer 48

Classifications:



External Ids:

Disease Ontology11 DOID:4897
MeSH39 D001650
SNOMED-CT62 70179006
NCIt45 C27814

Summaries for Bile Duct Carcinoma

About this section
MedlinePlus:38 Your liver makes a digestive juice called bile. your gallbladder stores it between meals. when you eat, your gallbladder pushes the bile into tubes called bile ducts. they carry the bile to your small intestine. the bile helps break down fat. it also helps the liver get rid of toxins and wastes. bile duct cancer is rare. it can happen in the parts of the bile ducts that are outside or inside the liver. cancer of the bile duct outside of the liver is much more common. risk factors include having inflammation of the bile duct, ulcerative colitis, and some liver diseases. symptoms can include jaundice itchy skin fever abdominal pain tests to diagnose bile duct cancer may include a physical exam, imaging tests of the liver and bile ducts, blood tests, and a biopsy. treatments include surgery, radiation therapy, and chemotherapy. nih: national cancer institute

MalaCards based summary: Bile Duct Carcinoma, also known as bile duct cancer, is related to intrahepatic cholangiocarcinoma and klatskin's tumor, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Bile Duct Carcinoma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways are Vinka Alkaloid Pathway, Pharmacokinetics and Defective GALNT12 causes colorectal cancer 1 (CRCS1). Affiliated tissues include liver, testes and pancreas, and related mouse phenotypes are integument and cardiovascular system.

Disease Ontology:11 A bile duct cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia:71 Cholangiocarcinoma or bile duct cancer is a form of cancer that is composed of mutated epithelial cells... more...

Related Diseases for Bile Duct Carcinoma

About this section

Diseases related to Bile Duct Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 226)
idRelated DiseaseScoreTop Affiliating Genes
1intrahepatic cholangiocarcinoma32.5CDX2, KRT7, MUC2
2klatskin's tumor31.9CDX2, KRT20, KRT7
3extrahepatic bile duct adenocarcinoma31.7CDH1, CDX2, KRT20, MUC1, MUC2, TP53
4liver disease30.1KRT19, MUC1, MUC4
5peritonitis30.0KRT20, KRT7
6renal cell carcinoma29.0CDH1, KRT19, KRT20, KRT7, MUC1
7adenosquamous bile duct carcinoma12.3
8bile duct carcinoma in situ12.1
9common bile duct neoplasm12.1
10cholangiocarcinoma, susceptibility to11.4
11biliary tract neoplasm11.2
12bile duct adenocarcinoma11.0
13distal biliary tract carcinoma11.0
14extrahepatic bile duct small cell adenocarcinoma11.0
15oral tuberculosis10.8CDH1, TP53
16glottis squamous cell carcinoma10.7CDX2, MUC2
17infiltrating lipoma10.7PTGS2, TP53
18renal pelvis inverted papilloma10.7CDH1, TP53
19giant cell myocarditis10.6CDH1, KRT20
20moderately severe hemophilia a10.6MUC2, MUC4
21pancreatic endocrine carcinoma10.6MUC1, MUC2
22scotoma10.6MUC1, MUC2, MUC4
23active cochleovestibular meniere's disease10.6CCND1, PTGS2
24apocrine adenocarcinoma10.6CDX2, MUC1, MUC2
25comedo carcinoma10.6CDH1, KRT20, MUC1
26integumentary system cancer10.6CCND1, CDH1, TP53
27adenomyosis10.6CDX2, MUC1, MUC2
28plasmacytic leukemia10.6MUC1, MUC2, MUC4
29breast pericanalicular fibroadenoma10.6KRT20, MUC1, MUC2
30pyloric antrum cancer10.6CDH1, CDX2, MUC2
31iris disease10.6CDX2, KRT20, MUC1
32hodgkin's granuloma10.6CCND1, CDH1, TP53
33myoepithelial carcinoma10.6MUC1, MUC4, TP53
34appendix adenocarcinoma10.6CDX2, KRT20, MUC2
35benign mesenchymoma10.6CDX2, KRT20, MUC1
36lobular neoplasia10.6CCND1, CDH1, TP53
37chronic eustachian salpingitis10.6CDX2, KRT20, TP53
38carbuncle10.6KRT20, MUC2
39spastic ataxia 310.6CDX2, KRT20, TP53
40pediatric germ cell cancer10.6CDX2, PTGS2, TP53
41fallopian tube carcinoma10.6CDH1, MUC1, MUC2, TP53
42chondroma10.5CCND1, CDH1, TP53
4312p12.1 microdeletion syndrome10.5CDH1, FASLG, MUC2
44bilateral retinoblastoma10.5CCND1, MYC, TP53
45richter's syndrome10.5CCND1, CDH1, MUC1, TP53
46epithelioid trophoblastic tumor10.5KRT20, MUC1, MUC2, TP53
47pharynx cancer10.5CCND1, MYC, TP53
48ascending colon cancer10.5CCND1, MYC, TP53
49penis carcinoma in situ10.5KRT20, PTGS2, TP53
50retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities10.5CDX2, PTGS2, TP53

Graphical network of the top 20 diseases related to Bile Duct Carcinoma:



Diseases related to bile duct carcinoma

Symptoms & Phenotypes for Bile Duct Carcinoma

About this section

UMLS symptoms related to Bile Duct Carcinoma:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107719.2ABCC3, CCND1, CDH1, FASLG, KRT19, MYC
2MP:00053859.2CCND1, CDH1, CDX2, FASLG, KRT19, MUC2
3MP:00053819.2CCND1, CDH1, CDX2, FASLG, KRT19, MUC2
4MP:00053799.1CCND1, CDH1, CDX2, FASLG, KRT19, MUC2
5MP:00020068.4CCND1, CDH1, CDX2, FASLG, KRT19, MUC2
6MP:00053847.9ANXA8L1, CCND1, CDH1, CDX2, FASLG, KRT19

Drugs & Therapeutics for Bile Duct Carcinoma

About this section

Drugs for Bile Duct Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 264)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Propofolapproved, investigational, vet_approvedPhase 410282078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
2
Midazolamapproved, illicitPhase 468459467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
 
Dormicum
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
3
Hydrocortisoneapproved, vet_approvedPhase 464050-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
4
EtomidateapprovedPhase 46333125-97-236339, 667484
Synonyms:
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-Etomidate
(+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-etomidate
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
(d)-Etomidate
1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester
1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester
15301-65-2
1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
33125-97-2
AC-5898
AC1L1VLF
AC1Q34BV
AC1Q64LP
AKOS000548952
Absele
Amidate
Amidate (TN)
Amidate (pharmaceutical)
Amidate, Etomidate
BAS 01947657
BRN 0665833
C07522
C14H16N2O2
CHEBI:129025
CHEMBL23731
CID36339
CPD000010931
D-Etomidate
D005045
D00548
 
DB00292
EINECS 251-385-9
Ethnor
Ethomidate
Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
Etomidate
Etomidate (USAN/INN)
Etomidate [USAN:BAN:INN]
Etomidato
Etomidato [INN-Spanish]
Etomidatum
Etomidatum [INN-Latin]
Etomidic acid
HMS1571A04
HMS1612G10
HMS2093P17
Hypnomidate
LS-78232
MLS000034952
MLS001240191
MolPort-000-917-569
Prestwick0_001041
Prestwick1_001041
Prestwick2_001041
R 16659
R 26490
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
R-26490
R26490
Radenarcon
Radenarkon
S1329_Selleck
SAM002548930
SBB066197
SMR000010931
SPBio_002901
UNII-Z22628B598
ethyl 3-(1-phenylethyl)imidazole-4-carboxylate
5
Oxaliplatinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1141261825-94-35310940, 9887054, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
6
PancrelipaseapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 193553608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
7
MeperidineapprovedPhase 47157-42-14058
Synonyms:
1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]
1-Methyl-4-phenylisonipecotic acid, ethyl ester
1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester
4-Carbethoxy-1-methyl-4-phenylpiperidine
4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester
50-13-5 (hydrochloride)
57-42-1
610593_ALDRICH
610593_FLUKA
AC1L1HBJ
C07128
CHEBI:122528
CHEMBL607
CID4058
D008614
D08343
DB00454
DEA No. 9230
Demarol
Demerol
DivK1c_000983
Dolcontral
Dolosal
Dolsin
EINECS 200-329-1
Ethyl 1-methyl-4-phenylisonipecotate
Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
HSDB 3116
IDI1_000983
Isonipecain
Isonipecaine
Isonipecaïne
Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester
KBio1_000983
 
L000908
LS-85121
Lidol
Lydol
Meperidine
Meperidine solution
Meperidol
Methyl phenylpiperidine carbonic acid ethyl ester
MolPort-001-785-564
N-Methyl-4-phenyl-4-carbethoxypiperidine
NINDS_000983
Nemerol
Operidine EPJ I
Operidine EPJ-I
Pethanol
Pethidin
Pethidine
Pethidine (INN)
Pethidine DBL
Pethidine DBL (TN)
Pethidine dbl
Pethidineter
Pethidinum
Pethidinum [INN-Latin]
Petidina
Petidina [INN-Spanish]
Petydyna
Petydyna [Polish]
Phetidine
Piperosal
Pipersal
Péthidine
Sauteralgyl
Spasmedal
Spasmodolin
UNII-9E338QE28F
YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI)
meperidine
8
Amoxicillinapproved, vet_approvedPhase 444126787-78-033613, 2171
Synonyms:
(-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid
(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
26787-78-0
33911-69-2
34642-77-8 (mono-hydrochloride salt)
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI)
6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid
6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(a-Amino-4-hydroxyphenylacetamido)penicillanic acid
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid
6-[[Amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9CI
61336-70-7 (TRIHYDRATE)
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
71447-36-4
81030-75-3
AC-12263
AC1L1PY2
AMC
AMOXICILLIN CRYSTALLINE
AMOXICILLIN PEDIATRIC
AMPC
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
AUGMENTIN '875'
AUGMENTIN ES-600
AX
Actimoxi
Almodan
Ambap26787-78-0
Amix
Amoclen
Amolin
Amopen
Amopenixin
Amoram
Amox
Amox 250 Cap 250mg
Amox 500 Cap 500mg
Amox S 125 Sus 125mg/5ml
Amox S 250 Sus 250mg/5ml
Amoxi
Amoxi-Mast
Amoxi-mast
Amoxibiotic
Amoxicaps
Amoxicilina
Amoxicilina [INN-Spanish]
Amoxicillin (INN)
Amoxicillin (TN)
Amoxicillin (anhydrous)
Amoxicillin (inn)
Amoxicillin Trihydrate
Amoxicillin and clavulanate potassium
Amoxicillin anhydrous
Amoxicillin pediatric
Amoxicillin trihydrate
Amoxicillin(usan)
Amoxicilline
Amoxicilline [INN-French]
Amoxicilline [INN]
Amoxicilline [inn]
Amoxicillinum
Amoxicillinum [INN-Latin]
Amoxid
Amoxiden
Amoxil
Amoxivet
Amoxycillin
Amoxycillin Trihydrate
Amoxycillin trihydrate
Amoxycillin, BAN
Amoxymed
Amrit
Anemolin
Apo-Amoxi
Apo-Amoxi Cap 250mg
Apo-Amoxi Cap 500mg
Apo-Amoxi Pwr for Susp 125mg/5ml
Apo-Amoxi Pwr for Susp 250mg/5ml
Apo-amoxi
Apo-amoxi sugar free
Aspenil
BL-P 1410
BLP 1410
BPBio1_000499
BRD-K55044200-001-03-9
BRL 2333
BRL-2333
BSPBio_000453
 
Biomox
Bristamox
C06827
CHEBI:2676
CHEBI:53712
CHEMBL1082
CID33613
CPD000058707
Cemoxin
Clamoxyl
Clamoxyl (SKB)
D-(-)-alpha-Amino-p-hydroxybenzyl penicillin
D-(-)-alpha-Amino-p-hydroxybenzylpenicillin
D-(alpha-Amino-p-hydroxybenzyl)penicillin
D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid
D-Amoxicillin
D07452
DB01060
Delacillin
DisperMox
Dispermox
EINECS 248-003-8
Efpenix
Flemoxin
Galenamox
Gen-Amoxicillin 250mg
Gen-Amoxicillin 500mg
HMS1569G15
HSDB 3204
Hiconcil
Histocillin
Hydroxyampicillin
Ibiamox
Imacillin
LS-149721
Lamoxy
Larotid
MLS000028632
MLS002222248
Metafarma capsules
Metifarma capsules
MolPort-003-981-182
MolPort-005-933-687
Moxacin
Moxal
Moxatag
NCGC00179554-01
NSC 277174
NSC277174
Novamoxin Cap 250mg
Novamoxin Cap 500mg
Novamoxin Sus 125mg/5ml
Novamoxin Sus 250mg/5ml
Nu-Amoxi Cap 250mg
Nu-Amoxi Cap 500mg
Nu-Amoxi Sus 125/5ml
Nu-Amoxi Sus 250mg/5ml
Ospamox
P-Hydroxyampicillin
PHL-amoxicillin
PMS-amoxicillin
Pamoxicillin
Piramox
Polymox
Prestwick0_000357
Prestwick1_000357
Prestwick2_000357
Prestwick3_000357
Prestwick_713
Prevpac
Pro Amox Pwr for Oral Susp 125mg/5ml
Pro Amox-250 Cap 250mg
Pro Amox-500 Cap 500mg
Pro-Amox-250 Orl Sus 250mg/5ml
R-Hydroxyampicillin
Rimoxallin
Ro 10-8756
Robamox
SAM002264592
SMR000058707
SPBio_002374
Sauracillin
Sawamox PM
Sumox
Tolodina
Trimox
Unicillin
Utimox
Vetramox
Wymox
Zimox
alpha-Amino-p-hydroxybenzylpenicillin
alpha-amino-P-Hydroxybenzylpenicillin
amoxicillanyl
amoxicillin
p-Hydroxyampicillin
α-amino-p-hydroxybenzylpenicillin
9
Coal tarapprovedPhase 41918007-45-2
Synonyms:
 
Coal tars
Tar, coal
10
Celecoxibapproved, investigationalPhase 4435169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
11
butyric acidexperimentalPhase 4363107-92-6264
Synonyms:
1-Butanoate
1-Butanoic acid
1-Butyrate
1-Butyric acid
1-Propanecarboxylate
1-Propanecarboxylic acid
Butanate
Butanic acid
Butanoate
Butanoic acid
Buttersaeure
Butyrate
 
Butyric acid
Ethylacetate
Ethylacetic acid
Honey robber
Kyselina maselna
N-Butanoate
N-Butanoic acid
N-Butyrate
N-Butyric acid
Propanecarboxylate
Propanecarboxylic acid
Propylformate
Propylformic acid
12Tranquilizing AgentsPhase 4, Phase 34164
13AnestheticsPhase 4, Phase 39001
14pancreatinPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1935
15Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 13868
16Fibrin Tissue AdhesivePhase 4145
17Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 117734
18Anti-Bacterial AgentsPhase 4, Phase 2, Phase 110884
19Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 18109
20Anesthetics, IntravenousPhase 4, Phase 32406
21Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
22Antibiotics, AntitubercularPhase 4, Phase 2, Phase 16972
23HemostaticsPhase 41359
24Psychotropic DrugsPhase 4, Phase 36279
25Anesthetics, GeneralPhase 4, Phase 32787
26Hypnotics and SedativesPhase 4, Phase 12485
27Cortisol succinatePhase 4640
28Central Nervous System DepressantsPhase 4, Phase 3, Phase 112806
29Anti-Anxiety AgentsPhase 4, Phase 31816
30Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 110355
31GABA ModulatorsPhase 4, Phase 1864
32GABA AgentsPhase 4, Phase 11622
33Hydrocortisone-17-butyratePhase 4318
34Hydrocortisone 17-butyrate 21-propionatePhase 4640
35Hydrocortisone acetatePhase 4640
36Adjuvants, AnesthesiaPhase 4, Phase 31588
37Antirheumatic AgentsPhase 4, Phase 110627
38NarcoticsPhase 4, Phase 33486
39Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
40AnalgesicsPhase 4, Phase 311287
41Analgesics, OpioidPhase 4, Phase 33091
42Cyclooxygenase InhibitorsPhase 42778
43Cyclooxygenase 2 InhibitorsPhase 4616
44Analgesics, Non-NarcoticPhase 46260
45Anti-Inflammatory Agents, Non-SteroidalPhase 44295
46arginineNutraceuticalPhase 4408
47Omega 3 Fatty AcidNutraceuticalPhase 4, Phase 1969
48ColaNutraceuticalPhase 4, Phase 3, Phase 1, Phase 21881
49
FluorouracilapprovedPhase 2, Phase 3, Phase 1179151-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
50
Capecitabineapproved, investigationalPhase 3, Phase 2, Phase 11296154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate

Interventional clinical trials:

(show top 50)    (show all 332)
idNameStatusNCT IDPhase
1Effects of Preoperative Immunonutrition in Patients Undergoing HepatectomyUnknown statusNCT01256047Phase 4
2Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerUnknown statusNCT00274885Phase 4
3Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar StrictureUnknown statusNCT01125865Phase 4
4Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cmUnknown statusNCT01351194Phase 4
5Additional Effects of Perioperative Immunonutrition in Patients Undergoing PancreaticoduodenectomyUnknown statusNCT01969110Phase 4
6Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant JaundiceUnknown statusNCT00731419Phase 4
7Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in ChildrenUnknown statusNCT02013986Phase 4
8Effects of Preoperative Immunonutrition in Patients Undergoing PancreaticoduodenectomyCompletedNCT01256034Phase 4
9Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of OddiCompletedNCT01041612Phase 4
10Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary ObstructionCompletedNCT00280709Phase 4
11RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant ObstructionCompletedNCT00980889Phase 4
12Covered vs. Uncovered SEMS for Occluded Biliary Metal StentsCompletedNCT01315522Phase 4
13Radiofrequency Ablation for Malignant Biliary ObstructionCompletedNCT01758341Phase 4
14The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic StentCompletedNCT01862198Phase 4
15Spy II Clinical RegistryCompletedNCT00751998Phase 4
16Etomidate vs. Midazolam for Sedation During ERCPCompletedNCT02027311Phase 4
17Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct ObstructionRecruitingNCT01514214Phase 4
18Lipidomics, Proteomics, Micro RNAs and Volatile Organic CompoundsRecruitingNCT02531607Phase 4
19Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute CholecystitisRecruitingNCT02057679Phase 4
20Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCCActive, not recruitingNCT02535117Phase 4
21Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas CancerEnrolling by invitationNCT01111591Phase 4
22The Effect of Individualized Precision Therapy Programs in Patients With BTCNot yet recruitingNCT02943031Phase 4
23Laparoscopic Surgery VS RFA for Recurrent HCCNot yet recruitingNCT02785380Phase 4
24A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary ObstructionTerminatedNCT01514058Phase 4
25Early Enteral Feeding After Pylorus Preserving PancreatoduodenectomyUnknown statusNCT00809081Phase 3
26Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the Pancreatic HeadUnknown statusNCT00753441Phase 2, Phase 3
27Evaluation of A New Digestive Reconstruction Procedure Following PancreatoduodenectomyUnknown statusNCT01931449Phase 3
28Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable CholangiocarcinomaUnknown statusNCT01739465Phase 2, Phase 3
29Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by SurgeryCompletedNCT01313377Phase 3
30Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by SurgeryCompletedNCT00513539Phase 3
31Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract TumorsCompletedNCT00262769Phase 3
32Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By SurgeryCompletedNCT00304135Phase 2, Phase 3
33Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract CancerCompletedNCT00363584Phase 3
34Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related SymptomsCompletedNCT01640522Phase 3
35Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
36Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper AbdomenCompletedNCT00016380Phase 3
37E-MOSAIC Electronic Tool to Monitor SymptomsCompletedNCT00477919Phase 3
38A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct ObstructionCompletedNCT00433771Phase 3
39S-1 and Photodynamic Therapy in CholangiocarcinomaCompletedNCT00869635Phase 3
40Clinical Outcomes of EUS-guided Biliary Drainage Using Partially or Fully Covered Metallic StentsCompletedNCT02114320Phase 3
41Comparison on the Efficacy of Endoscopic Snare Papillectomy With or Without Submucosal InjectionCompletedNCT02165852Phase 3
42Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus PancreaticojejunostomyCompletedNCT00830778Phase 3
43Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the PancreasCompletedNCT00844649Phase 3
44Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct TumoursRecruitingNCT02591030Phase 2, Phase 3
45RFA RCT for Pancreatic or Bile Duct CancerRecruitingNCT02166190Phase 3
46Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct StricturesRecruitingNCT01721174Phase 2, Phase 3
47Photodynamic Therapy (PDT) for Palliation of CholangiocarcinomaRecruitingNCT01755013Phase 2, Phase 3
48Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line ChemotherapyRecruitingNCT02853474Phase 3
49Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family CaregiversRecruitingNCT02349412Phase 3
50Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic CholangiocarcinomaRecruitingNCT02798510Phase 3

Search NIH Clinical Center for Bile Duct Carcinoma


Cochrane evidence based reviews: bile duct neoplasms

Genetic Tests for Bile Duct Carcinoma

About this section

Anatomical Context for Bile Duct Carcinoma

About this section

MalaCards organs/tissues related to Bile Duct Carcinoma:

36
Liver, Testes, Pancreas, Small intestine, Lung, Skin, Breast

Publications for Bile Duct Carcinoma

About this section

Articles related to Bile Duct Carcinoma:

(show top 50)    (show all 301)
idTitleAuthorsYear
1
EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma. (27020207)
2016
2
Bile duct carcinoma recurrence in the papillary region in a long-term survivor of hilar cholangiocarcinoma: a case report. (27784337)
2016
3
Bile duct carcinoma associated with congenital biliary dilatation in a 16-year-old female: a case report and literature review. (26943681)
2016
4
Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. (26956004)
2016
5
Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas. (27469329)
2016
6
Abnormal increased re-released Hb from RBCs of an intrahepatic bile duct carcinoma patient was detected by electrophoresis release test. (26405982)
2015
7
Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma. (26423666)
2015
8
Bilateral ovarian metastasis from distal common bile duct carcinoma developing after choledochal cyst excision. (26155281)
2015
9
Polypoid extrahepatic bile duct carcinoma morphologically indistinguishable from benign giant cell tumor. (26256450)
2015
10
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. (26001650)
2015
11
When hepatic-side ductal margin is positive in N+ cases, additional resection of the bile duct is not necessary to render the negative hepatic-side ductal margin during surgery for extrahepatic distal bile duct carcinoma. (24657986)
2014
12
A novel technique for endoscopic transpapillary "mapping biopsy specimens" of superficial intraductal spread of bile duct carcinoma (with videos). (24674353)
2014
13
A case of occupational bile duct carcinoma following exposure to a chlorinated organic solvent in the printing industry that was recognized as a work-related accident. (25482911)
2014
14
How to access photodynamic therapy for bile duct carcinoma. (25332999)
2014
15
Characterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinoma. (23382894)
2013
16
Diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy samples of extrahepatic bile duct carcinoma. (23269460)
2013
17
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma. (22835954)
2013
18
Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. (24289902)
2013
19
Pancreaticobiliary maljunction is associated with common bile duct carcinoma: a meta-analysis. (24489507)
2013
20
Bile duct carcinoma involving the common channel associated with pancreaticobiliary maljunction shows an extension pattern similar to ductal carcinoma of the pancreas. (23957917)
2013
21
Differential expression of basement membrane type IV collagen I+2 and I+6 chains as a prognostic factor in patients with extrahepatic bile duct carcinoma. (22927259)
2013
22
Descriptive epidemiology of bile duct carcinoma in Osaka. (24014885)
2013
23
Photodynamic therapy using talaporfin sodium (LaserphyrinAr) for bile duct carcinoma: a preliminary clinical trial. (23155262)
2012
24
Adenocarcinoma with pyloric gland phenotype of the extrahepatic bile ducts: a previously unrecognized and distinctive morphologic variant of extrahepatic bile duct carcinoma. (22795356)
2012
25
Bile aspiration cytology in diagnosis of bile duct carcinoma: factors associated with positive yields. (21785970)
2012
26
Extended right hepatectomy for hilar bile duct carcinoma using the modified liver hanging maneuver. (22683977)
2012
27
Duct of Luschka diagnosed by sonography in a patient with bile duct carcinoma and intrahepatic bile duct dilatation. (23055263)
2012
28
Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma. (21360081)
2011
29
Post-cholecystectomy amputation neuroma mimicking common bile duct carcinoma. (21861328)
2011
30
Endoscopic diagnosis of extrahepatic bile duct carcinoma: Advances and current limitations. (21611097)
2011
31
Aggressive hilar inflammatory myofibroblastic tumor with hilar bile duct carcinoma in situ. (22319741)
2011
32
Down-regulation of c-Myc expression inhibits the invasion of bile duct carcinoma cells. (21557726)
2011
33
Extensively spreading intraepithelial bile duct carcinoma causing multiple bile duct strictures: report of three cases. (21969205)
2011
34
Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. (20459570)
2010
35
Pancreatoduodenectomy for local intrapancreatic recurrence after bile duct resection of mid bile duct carcinoma. (21410028)
2010
36
Decreased expression of focal adhesion kinase is associated with a poor prognosis in extrahepatic bile duct carcinoma. (20185162)
2010
37
Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. (19521656)
2010
38
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. (20224968)
2010
39
The ratio between metastatic and examined lymph nodes is an independent prognostic factor for patients with resectable middle and distal bile duct carcinoma. (19596119)
2010
40
A novel approach for treatment of unresectable extrahepatic bile duct carcinoma: design of radioactive stents and an experimental trial in healthy pigs. (19231492)
2009
41
Choleretic effect of inchinkoto, a herbal medicine, on livers of patients with biliary obstruction due to bile duct carcinoma. (19054142)
2009
42
67-kDa laminin receptor in human bile duct carcinoma. (19182490)
2009
43
Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. (19460356)
2009
44
Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinoma. (19420730)
2009
45
Usefulness of measuring hepatic functional volume using Technetium-99m galactosyl serum albumin scintigraphy in bile duct carcinoma: report of two cases. (19183831)
2009
46
Prognostic significance of fascin expression in extrahepatic bile duct carcinomas. (19556073)
2009
47
Main bile duct carcinoma management. Our experience on 38 cases. (19681291)
2009
48
Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. (19628081)
2009
49
Three-dimensional cholangiography applying C-arm computed tomography in bile duct carcinoma: a new radiological technique. (19621666)
2009
50
Pyogenic liver abscess complicating early bile duct carcinoma in the middle bile duct: a rare presentation. (19252355)
2009

Variations for Bile Duct Carcinoma

About this section

Cosmic variations for Bile Duct Carcinoma:

8
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM521KRASbiliary tract,gallbladder,other,inflammationc.35G>Ap.G12D4

Expression for genes affiliated with Bile Duct Carcinoma

About this section
Search GEO for disease gene expression data for Bile Duct Carcinoma.

Pathways for genes affiliated with Bile Duct Carcinoma

About this section

Pathways related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
idSuper pathwaysScoreTop Affiliating Genes
110.0ABCC2, ABCC3
2
Show member pathways
9.9MUC1, MUC2, MUC4
39.8CCND1, MYC, TP53
49.8CCND1, MYC, TP53
59.8CCND1, MYC, TP53
69.8CCND1, CDH1, MYC
79.8CCND1, MYC, PTGS2
89.7KRT19, PTGS2, TP53
9
Show member pathways
9.7CCND1, CDH1, MYC, TP53
10
Show member pathways
9.7CCND1, CDH1, MYC, TP53
119.7CCND1, CDH1, MYC, TP53
129.7CCND1, CDH1, MYC, TP53
139.7CCND1, CDH1, MYC, TP53
149.6CCND1, MYC, PTGS2, TP53
15
Show member pathways
9.5CCND1, FASLG, MYC, TP53
169.5CCND1, FASLG, MYC, TP53
179.5CCND1, CDH1, MYC, PTGS2, TP53
189.5CCND1, CDH1, MYC, PTGS2, TP53
199.3CCND1, FASLG, MYC, PTGS2, TP53
209.3CDX2, KRT19, MYC, NCAM1
219.1CCND1, CDH1, FASLG, MYC, PTGS2, TP53

GO Terms for genes affiliated with Bile Duct Carcinoma

About this section

Cellular components related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1intermediate filamentGO:00058829.2KRT19, KRT20, KRT7, KRT9
2extracellular exosomeGO:00700627.7ANXA8L1, CDH1, FASLG, KRT19, KRT7, KRT9

Biological processes related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.8MUC1, TP53
2mitotic G1 DNA damage checkpointGO:003157110.8CCND1, TP53
3maintenance of gastrointestinal epitheliumGO:003027710.8MUC2, MUC4
4ovulationGO:003072810.7MYC, PTGS2
5re-entry into mitotic cell cycleGO:000032010.7CCND1, MYC
6O-glycan processingGO:001626610.6MUC1, MUC2, MUC4
7cellular chloride ion homeostasisGO:003064410.6ABCC2, FASLG
8cellular response to UVGO:003464410.5MYC, PTGS2, TP53
9response to estrogenGO:004362710.1ABCC2, CCND1, KRT19
10positive regulation of cell proliferationGO:00082849.9CCND1, CDX2, FASLG, MYC, PTGS2
11response to drugGO:00424939.9ABCC2, CCND1, CDH1, MYC, PTGS2
12response to organic substanceGO:00100339.4CCND1, CDH1, PTGS2, S100P

Molecular functions related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

   (show less)
idNameGO IDTop Affiliating Genes

Sources for Bile Duct Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet